Dialysis News and Research RSS Feed - Dialysis News and Research

When your kidneys are healthy, they clean your blood. They also make hormones that keep your bones strong and your blood healthy. When your kidneys fail, you need treatment to replace the work your kidneys used to do. Unless you have a kidney transplant, you will need a treatment called dialysis.

There are two main types of dialysis: hemodialysis and peritoneal dialysis. Both types filter your blood to rid your body of harmful wastes, extra salt and water. Hemodialysis does that with a machine. Peritoneal dialysis uses the lining of your abdomen, called the peritoneal membrane, to filter your blood. Each type has both risks and benefits. They also require that you follow a special diet. Your doctor can help you decide the best type of dialysis for you.
Newly developed agent filters out toxins from body in the event of overdose

Newly developed agent filters out toxins from body in the event of overdose

Every minute counts in the event of an overdose. ETH professor Jean-Christophe Leroux and his team have developed an agent to filter out toxins from the body more quickly and efficiently. [More]
New surface coating for medical devices prevents blood from clotting

New surface coating for medical devices prevents blood from clotting

From joint replacements to cardiac implants and dialysis machines, medical devices enhance or save lives on a daily basis. However, any device implanted in the body or in contact with flowing blood faces two critical challenges that can threaten the life of the patient the device is meant to help: blood clotting and bacterial infection. [More]

DaVita HealthCare Partners honored with 2014 CBC Fall Health Braintrust Corporate Leadership Award

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, was recently recognized by the Congressional Black Caucus Foundation with the 2014 CBC Fall Health Braintrust Corporate Leadership Award. [More]

Cantel Medical achieves record revenue growth in fourth quarter 2014

CANTEL MEDICAL CORP. reported net income of $10,705,000, or $0.26 per diluted share, on a 15% increase in sales to a record $131,377,000 for the fourth quarter ended July 31, 2014, inclusive of $0.02 for charges related to acquisition and CFO retirement costs. [More]
Cedars-Sinai scientists test ELAD bioartificial liver support system for patients with acute liver failure

Cedars-Sinai scientists test ELAD bioartificial liver support system for patients with acute liver failure

Cedars-Sinai physicians and scientists are testing a novel, human cell based, bioartificial liver support system for patients with acute liver failure, often a fatal diagnosis. [More]
Highlights: Hawaii public hospital cuts; La. struggles with state worker health program costs; aging in Ky.

Highlights: Hawaii public hospital cuts; La. struggles with state worker health program costs; aging in Ky.

Public hospitals across Hawaii are finding ways to reduce staff and cut services because they don't have enough money to make ends meet. Executives from the Hawaii Health Systems Corp. told lawmakers Friday that even after layoffs they are facing a $30 million deficit in 2015. One hospital on Maui chose to close its adolescent psychology unit because it couldn't sustain the appropriate staffing levels to provide the services. It's also considering cuts to oncology and dialysis services if the situation doesn't improve (9/20). [More]
Falcon Physician certified for Meaningful Use Stage 2

Falcon Physician certified for Meaningful Use Stage 2

Falcon Physician, a provider of electronic health record (EHR) software to nephrologists and a subsidiary of DaVita HealthCare Partners, a leading provider of kidney care and health care services, announced that it has successfully completed the rigorous requirements needed to become certified for Meaningful Use Stage 2. [More]
Gilead to boost price of new hepatitis c drug

Gilead to boost price of new hepatitis c drug

Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries. [More]
New iodine-based contrast material enhances CT images to safely use in most patients

New iodine-based contrast material enhances CT images to safely use in most patients

According to new research performed at the Mayo Clinic, iodine-based contrast material injected intravenously to enhance computed tomography (CT) images can be safely used in most patients. The study appears online in the journal Radiology. [More]
FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). [More]
FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. [More]
DaVita Kidney Care hosts online Google+ Hangout on Air

DaVita Kidney Care hosts online Google+ Hangout on Air

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, will host an online Google+ Hangout on Air called "Kidney Diet Tips: Diabetes Edition" on Monday, Sept. 8 at 5:00 p.m. PT/8:00 p.m. ET. [More]
Clinical studies to treat unmet medical need post-transplantation

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function [More]
Researchers create new drug to reduce inflammation of donor organ after transplantation

Researchers create new drug to reduce inflammation of donor organ after transplantation

To reduce the number of discards and thus make more kidneys available, researchers and medical scientists from the European consortium MABSOT have created a new drug called OPN-305 to reduce inflammation of the donor organ after transplantation. [More]
‘Concerning’ rise in pneumococcus risk factors

‘Concerning’ rise in pneumococcus risk factors

Researchers report that the incidence of Streptococcus pneumoniae infection has fallen significantly in the USA in the past decade but describe a “concerning trend” whereby the baseline health status of those with serious pneumococcal disease has worsened. [More]
'Good' cholesterol turns 'bad' by sugar-derived substance

'Good' cholesterol turns 'bad' by sugar-derived substance

Scientists at the University of Warwick have discovered that 'good' cholesterol is turned 'bad' by a sugar-derived substance. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. [More]
Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy. [More]

DaVita HealthCare Partners recognized as Metro Denver's healthiest extra-large employer

DaVita HealthCare Partners Inc., a leading provider of kidney care and health care services, today announced it has been recognized by the Denver Business Journal as Metro Denver's healthiest extra-large employer. This is the third consecutive year the publication has recognized the company's commitment to teammate health and wellness with a first place rank in the Healthiest Employer award program. [More]